Evidence map›Paper›PMID 34246984›Full record

ArticleNeoplasia (New York, N.Y.)2021

Plasma proteome alterations by MAPK inhibitors in BRAF

Haris Babačić, Hanna Eriksson, Maria Pernemalm

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Neoplasia (New York, N.Y.), 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.1field-weighted citation impact, top 56% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 4 citations in OpenAlex.

  1. Article
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 2 institutions in 1 country.

Haris BabačićDepartment of Oncology-Pathology, Science for Life Laboratory, Karolinska Institute, Stockholm, Sweden.
Hanna ErikssonTheme Cancer / Department of Oncology, Karolinska University Hospital, Stockholm, Sweden. Electronic address: hanna.eriksson.4@ki.se.
Maria PernemalmDepartment of Oncology-Pathology, Science for Life Laboratory, Karolinska Institute, Stockholm, Sweden.
Science for Life Laboratory · SEKarolinska University Hospital · SE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Approximately half of metastatic cutaneous melanomas (CM) harbor a mutation in the BRAF protooncogene, upregulating the mitogen-activated protein kinase (MAPK)-pathway. The development of inhibitors targeting the MAPK pathway (MAPKi), i.e., BRAF- and MEK-inhibitors (BRAFi and MEKi), have substantially improved the survival in BRAF

Indexed as

Blood ProteinsMutationProteomeProteomicsAdultAgedCutaneous Malignant MelanomaDisease ManagementDisease SusceptibilityFemaleHumansMaleMass SpectrometryMelanomaMiddle AgedNeoplasm GradingBlood ProteinsBRAF protein, humanProtein Kinase InhibitorsProteomeProto-Oncogene Proteins B-rafBiomarkersBRAF and MEK inhibitorsMelanomaMitogen-activated protein kinasePlasma proteinsTargeted therapyV600E mutation

Identifiers

PMID34246984
PMCPMC8274243
OpenAlexW3181849782

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.